Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Pembrolizumab monotherapy has been approved for the first- and second-line treatment of patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC). Testing for PD-L1 expression with the PD-L1 immunohistochemistry (IHC) 22C3 companion diagnostic assay, which gives a tumor proportion s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Vis Exp
Autores principales: Ilié, Marius, Ngo-Mai, Mélanie, Long-Mira, Elodie, Lassalle, Sandra, Butori, Catherine, Bence, Coraline, Hamila, Marame, Hofman, Véronique, Hofman, Paul
Formato: Artigo
Lenguaje:Inglês
Publicado: MyJove Corporation 2018
Materias:
Cancer Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6235290/
https://ncbi.nlm.nih.gov/pubmed/30320751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3791/58082
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares